Rheumatology
News
Rheumatoid Arthritis Patients Not Receiving Proper Cardioprotective Medications
Major Finding: Odds ratios for the prescription of aspirin, a statin, and beta-blockers 30 days after a first MI were 0.75, 0.68, and 0.76,...
News
Rheumatoid Arthritis Incidence Rises With Age, Peaks During 70s
Major Finding: The incidence rate of newly diagnosed rheumatoid arthritis rises with age, peaking among people in their 70s with an incidence of...
News
NIAMS Celebrates 25 Years of Advances in Medical Research
News
Rheumatoid Arthritis Drug Trials Often Lack Comparator Regimens
Major Finding: A review of 17 recent clinical trials for three new rheumatoid arthritis drugs showed that only two of the trials placed patients...
News
Hereditary Hemochromatosis Linked to Increased Arthropathies and Joint Surgery
Major Finding: Patients with hereditary hemochromatosis had a 2.4-fold increased prevalence of arthropathies and a 2.9-fold increased rate of hip...
News
Tocilizumab Continues to Benefit sJIA Patients Over Time
Major Finding: Treatment with the interleukin-6 blocker tocilizumab led to ongoing improvements in 99 children with systemic juvenile idiopathic...
News
HPV Vaccine Does Not Induce Lupus Flares
Major Finding: The quadrivalent human papillomavirus vaccine does not exacerbate disease activity in women with SLE.Data Source: A prospective...
News
Fulranumab Shows Efficacy for Osteoarthritis Pain
Major Finding: Treatment with several different dosages of fulranumab led to statistically significant improvements in a number of efficacy...
News
RA and SLE Risk Factors Remain for Mothers and Babies
Major Finding: Adjusted odds ratios for preeclampsia or eclampsia were 2.8 (95% CI 1.0-7.8) for RA and 2.0 (95% CI 1.0-3.7) for SLE.Data Source:...
News
GI Perforation Rare in Rheumatoid Arthritis Patients
Major Finding: The incidence of GI perforation was highest in patients who used glucocorticoids in combination with DMARDs other than methotrexate...
News
SLE: Belimumab Safety, Efficacy Sustained Over 6 Years
Major Finding: The rate of severe disease flares in seropositive patients treated with belimumab decreased from 17% at year 1 to 5% at year 6 with...